← FDA DRUG APPROVALS
FDA ANDA · ANDA217813
DEFLAZACORT ORAL SUSPENSION
deflazacort oral
Sponsor: TRIS PHARMA INC
APPLICATION
ANDA217813
TYPE
ANDA
ORIGINAL APPROVAL
2024-04-25
LATEST ACTION
2024-10-29
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
DEFLAZACORTPrescription
DEFLAZACORT 22.75MG/ML · SUSPENSION · ORAL
Approval history
2024-10-29Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.